141 related articles for article (PubMed ID: 10170450)
1. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.
Erhardt L; Ball S; Andersson F; Bergentoft P; Martinez C
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):256-66. PubMed ID: 10170450
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
Schädlich PK; Huppertz E; Brecht JG
Pharmacoeconomics; 1998 Dec; 14(6):653-69. PubMed ID: 10346417
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.
Hart WM; Rubio-Terres C; Pajuelo F; González Juanatey JR
Eur J Heart Fail; 2002 Aug; 4(4):553-8. PubMed ID: 12167396
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
Grover SA; Coupal L; Lowensteyn I
Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
6. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.
Hall AS; Murray GD; Ball SG
Lancet; 1997 May; 349(9064):1493-7. PubMed ID: 9167457
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic impact of HOPE.
Ostergren JB; Björholt I; Andersson F; Kahan T
Int J Clin Pract Suppl; 2001 Jan; (117):19-21. PubMed ID: 11715354
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events.
Capri S; Perlini S
Curr Med Res Opin; 2005 Jun; 21(6):913-21. PubMed ID: 16003858
[TBL] [Abstract][Full Text] [Related]
10. [Added organ protection at little cost. Double savings with ACE inhibitors].
MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008
[No Abstract] [Full Text] [Related]
11. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.
Smith MG; Neville AM; Middleton JC
Intern Med J; 2003; 33(9-10):414-9. PubMed ID: 14511193
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.
Aurbach A; Russ W; Battegay E; Bucher HC; Brecht JG; Schädlich PK; Sendi P
Swiss Med Wkly; 2004 Jul; 134(27-28):399-405. PubMed ID: 15389357
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
Björholt I; Andersson FL; Kahan T; Ostergren J
J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
[TBL] [Abstract][Full Text] [Related]
14. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
Lamy A; Yusuf S; Pogue J; Gafni A;
Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
[TBL] [Abstract][Full Text] [Related]
15. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].
Hart WM; Rubio-Terrés C; Margalet Fernández I; González Juanatey JR
An Med Interna; 2002 Oct; 19(10):515-20. PubMed ID: 12481494
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.
Wu J; Hall AS; Gale CP;
Heart; 2021 Mar; 107(5):389-395. PubMed ID: 33452123
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Malik IS; Bhatia VK; Kooner JS
Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.
Carroll CA; Coen MM; Piepho RW
Ann Pharmacother; 2003 Mar; 37(3):327-31. PubMed ID: 12639157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
